Mictonorm (Propiverine Hydrochloride)

Mictonorm (propiverine) acts on the urinary bladder muscarinic receptors to alleviate overactive bladder symptoms.

• Overactive bladder: reduces frequency of involuntary bladder contractions, improving bladder storage capacity.
• Urinary urgency: lessens the sudden, compelling need to void.
• Urinary frequency: decreases the number of daytime voids.
• Urge urinary incontinence: helps prevent leakage associated with sudden urges.

• Propiverine hydrochloride competitively blocks muscarinic M3 receptors in the detrusor smooth muscle of the bladder. By inhibiting acetylcholine‑mediated signaling, it reduces involuntary muscle contractions, thereby increasing bladder capacity and decreasing urgency and frequency of voiding. The drug’s anticholinergic activity is selective for bladder tissue, limiting systemic cholinergic effects. The antagonism also modulates reflex pathways that control bladder emptying, contributing to a more stable storage phase without significantly affecting voiding efficiency.

Propiverine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dry mouth: reduced salivary secretion leading to thirst.
• Constipation: slowed gastrointestinal motility.
• Blurred vision: transient visual disturbances.
• Headache: mild to moderate head pain.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Acute urinary retention: inability to empty bladder requiring medical intervention.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Cardiac arrhythmia: irregular heartbeat, including QT prolongation.

When prescribing Mictonorm, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: assess kidney function and adjust therapy if needed.
• Hepatic impairment: monitor liver enzymes and use with caution in severe disease.
• Elderly patients: start with the lowest effective dose due to increased sensitivity.
• Concomitant anticholinergics: avoid additive anticholinergic burden.
• Driving or operating machinery: caution due to possible dizziness or visual changes.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Propiverine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase propiverine plasma levels and risk of toxicity.
• Other anticholinergic agents (e.g., oxybutynin, antihistamines): additive anticholinergic effects can exacerbate side effects.
• Drugs that prolong QT interval (e.g., erythromycin, fluoroquinolones): combined use may increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce propiverine effectiveness.
• Diuretics: may enhance risk of urinary retention.
• Antihypertensive agents: monitor blood pressure as anticholinergic effect may affect vascular tone.